Skip to main content
. 2022 May 6;39(5):110761. doi: 10.1016/j.celrep.2022.110761

Figure 2.

Figure 2

AMPK-α1 and not AMPK-α2 is specifically cleaved by caspase-3

Jurkat cells were pre-treated with Z-VAD-FMK (50 μM) for 1 h, followed by SNG (3 μM) and anti-Fas (25 ng) treatment for a further 4 h.

(A–C) Western blot analysis (A), caspase-3 activity (B; data shown are mean ± SD; n = 3; ∗∗p < 0.01 and ∗∗∗p < 0.001), and cell viability (C) were carried out (data shown are mean ± SD; n = 3; ∗∗∗p < 0.001).

(D) Western blots of lysates of MCF7 and Jurkat cells treated with indicated concentrations of Dox.

(E) Schematic representation of different AMPK-α constructs.

(F–H) HEK293 (F and G) and Jurkat (H) cells were transfected with the indicated plasmids, and in vitro caspase cleavage was performed in lysates in the presence or absence of Z-VAD-FMK (25 μM). Western blot analysis was carried out.

(I) In vitro caspase cleavage was performed using Jurkat cell lysates containing C-terminally GFP-tagged AMPK-α1 and different caspases. Western blot analysis was carried out. Asterisk indicates non-specific band.